Policosanol for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Policosanol for Health & Longevity

Created on 08/21/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A cheap waxy sugarcane extract taken once daily. Most cholesterol-lowering trials come from its Cuban maker; independent groups could not reproduce them. Small consistent blood pressure falls and a genuine reduction in platelet stickiness survive. Side effects are uncommon and mild. The live question is not danger but whether it does enough to earn a daily place. (Full Review)

Protocol

Standard dose
10–20 mg once daily
Sugarcane-derived policosanol, the range used in essentially every positive trial. Doses above 20 mg add no further effect.
Time of day
Evening, with the largest meal
Morning dosing is the standard alternative when sleep is disturbed. All positive trials used once-daily dosing.
Take with dietary fat
Fat-containing meal
Octacosanol is essentially water-insoluble, so a fat-containing meal is the only practical bioavailability lever.
Time to effect
Blood pressure
Around week 8
Twelve weeks is the standard trial length before judging response.
Antiplatelet effect
Within 30 days
Aggregation returns toward baseline over days to weeks after stopping.
Lipid changes
6–8 weeks
Where reported; plateau by 12 weeks.

Benefits

Contraindications
  • Pregnant or breastfeeding women
  • Active bleeding disorder (hemophilia, platelet count below 100 × 10⁹/L)
  • Within 7 days of planned surgery, dental extraction, or spinal or epidural anesthesia
  • Documented allergy to sugarcane derivatives or beeswax-derived wax alcohols
  • Sole therapy for familial hypercholesterolemia (untreated LDL cholesterol above 190 mg/dL) or established atherosclerotic cardiovascular disease
Key Interactions
  • Antiplatelet agents (aspirin, clopidogrel, prasugrel, ticagrelor): Caution
  • Anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran): Caution
  • Antihypertensives, especially beta-blockers (metoprolol, atenolol) and vasodilators: Monitor
  • Over-the-counter analgesics (ibuprofen, naproxen, high-dose aspirin): Caution
  • Antiplatelet supplements (fish oil, garlic, ginkgo, high-dose vitamin E, nattokinase): Caution
  • Blood-pressure-lowering supplements (beetroot nitrate, magnesium, hibiscus, potassium, garlic): Monitor
  • Other lipid-lowering interventions (red yeast rice, plant sterols, berberine, bergamot): Monitor
  • Statins (atorvastatin, simvastatin, rosuvastatin): No interaction identified

Risk & Side Effects

  • High: Failure to lower LDL cholesterol when used in place of proven therapy
  • Medium: Additive bleeding tendency with antiplatelet or anticoagulant drugs (conflicted)
  • Low: Central nervous system side effects; excessive blood pressure lowering in treated hypertension; brand-to-brand composition variability
  • Speculative: Skin rash and hypersensitivity; unknown safety beyond roughly three years

Monitoring

Marker Target Why
Apolipoprotein B (ApoB) < 80 mg/dL; < 60 mg/dL for high cardiovascular risk Counts artery-clogging particles directly; the primary success criterion
LDL cholesterol < 100 mg/dL; < 70 mg/dL for high risk The endpoint on which the entire policosanol controversy turns
HDL cholesterol 50–80 mg/dL (men); 60–90 mg/dL (women) Tests the one lipid claim that survives in supplier-run trials
Triglycerides < 80 mg/dL Confirms no adverse lipid shift; policosanol is not expected to move this
Seated blood pressure < 120/75 mmHg The best-supported policosanol benefit and the main hypotension risk
ALT and AST ALT 10–26 U/L (men), 8–22 U/L (women); AST 10–26 U/L Confirms the expected small fall rather than injury
Fasting glucose 75–86 mg/dL Captures the small glycemic effect seen in pooled trial data
Glycated hemoglobin (HbA1c) 4.8–5.3% Three-month average blood sugar; the endpoint in supplier-run Japanese work
Platelet count 200–350 × 10⁹/L Baseline safety check before adding an agent that inhibits platelet function
International normalized ratio (INR) Within the individual's therapeutic target; otherwise 0.9–1.1 Detects any real-world bleeding interaction in anticoagulated users
High-sensitivity C-reactive protein (hs-CRP) < 0.5 mg/L General inflammatory load; reported to fall in one elderly trial
Creatinine and eGFR Creatinine 0.7–1.1 mg/dL (men), 0.6–0.9 mg/dL (women); eGFR > 90 mL/min/1.73m² Kidney filtration; pooled data show no change, so any drift is unrelated

Cadence: Fasting baseline panel before the first dose; home blood pressure weekly for the first 4 weeks; full repeat panel at 12 weeks. If the 12-week panel shows movement, the panel repeats at 6 months and then every 6–12 months.

Qualitative Assessment

  • Sleep onset latency and night-time waking, since insomnia is the commonest reported complaint
  • Light-headedness on standing, which flags additive blood pressure lowering
  • Ease of bruising, gum bleeding after brushing, or prolonged bleeding from small cuts
  • Walking distance before onset of calf pain, where peripheral arterial disease is present
  • Headache frequency compared with the pre-treatment baseline
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.